Zobrazeno 1 - 10
of 266
pro vyhledávání: '"D M, Goldenberg"'
Autor:
S. Stenler, K. E. Lundin, L. Hansen, S. Petkov, N. Mozafari, M. Isaguliants, P. Blomberg, C. I. E. Smith, D. M. Goldenberg, C.-H. Chang, K. Ljungberg, J. Hinkula, B. Wahren
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 12, Pp 2849-2858 (2017)
Background: Genetic immunization is expected to induce the expression of antigens in a native form. The encoded peptide epitopes are presented on endogenous MHC molecules, mimicking antigen presentation during a viral infection. We have explored the
Externí odkaz:
https://doaj.org/article/ba7e0ede7ccb4c2db071810eddf1238f
Publikováno v:
British Journal of Cancer
Background: During metastasis, cancer cells migrate away from the primary tumour and invade the circulatory system and distal tissues. The stimulatory effect of growth factors has been implicated in the migration process. Placental growth factor (PlG
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1045d0ea9bc60bccf594ed3e5ab3b59d
http://europepmc.org/articles/PMC2905300
http://europepmc.org/articles/PMC2905300
Autor:
D M Goldenberg, R M Sharkey
Publikováno v:
Oncogene. 26:3734-3744
This article reviews the development of radioimmunoconjugates as a new class of cancer therapeutics. Numerous conjugates involving different antigen targets, antibody forms, radionuclides and methods of radiochemistry have been studied in the half-ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5928bc040494db620c5b6ea1ffbf72f7
https://doi.org/10.1038/sj.onc.1210373
https://doi.org/10.1038/sj.onc.1210373
Autor:
Julia A. O'Hara, Harold M. Swartz, Rosalyn D. Blumenthal, Stalina A. Grinberg, Eugene Demidenko, A. M. Taylor, Oleg Y. Grinberg, D. M. Goldenberg, Carmen M. Wilmot
Publikováno v:
Radiation Research. 155:466-473
The efficacy of radiation treatment depends upon local oxygen concentration. We postulated that the variability in responsiveness of tumor xenografts to a fixed dose of radioimmunotherapy might be related to the tumor pO2 at the time that radioimmuno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6984cb684431caf3053b3ce77cec39bb
https://doi.org/10.1667/0033-7587(2001)155[0466:rtrcwt]2.0.co
https://doi.org/10.1667/0033-7587(2001)155[0466:rtrcwt]2.0.co
Publikováno v:
Immunology. 98:296-302
We previously described the processing of antibodies to CD74 (the major histocompatibility complex class II-associated invariant chain, Ii), by B-cell lymphoma cell lines. These cells expressed relatively low levels of Ii on the surface, but the mole
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1f980a74737437bf4b0d226f1b79df0
https://doi.org/10.1046/j.1365-2567.1999.00868.x
https://doi.org/10.1046/j.1365-2567.1999.00868.x
Publikováno v:
Nuclear Medicine Communications. 18:142-148
LL1, a monoclonal antibody (MAb) to HLA Class-II-like antigen (li determinant) on the surface of B-lymphocytes, monocytes and histiocytes, was evaluated as an agent for bone marrow imaging. Six patients with diverse diseases (non-Hodgkin's lymphoma,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ca0dc9be4d2b0695d4fa72e41fc1202
https://doi.org/10.1097/00006231-199702000-00009
https://doi.org/10.1097/00006231-199702000-00009
Publikováno v:
The Journal of Immunology. 154:5919-5926
A natural N-linked glycosylation site (Asn-Val-Thr) at amino acid positions 18-20 (Kabat's numbering) was identified in the framework-1 (FR-1) region of the light chain variable (V kappa) domain of a murine anti-B cell lymphoma Ab, LL-2. Our earlier
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4a75c3f27bfcd952c9f652fcc464472
https://doi.org/10.4049/jimmunol.154.11.5919
https://doi.org/10.4049/jimmunol.154.11.5919
Publikováno v:
Cancer. 73:896-899
Background. Various monoclonal antibodies (MoAb) labeled with Iodine-131 or Indium-111 (In-111) have been investigated for radioimmunodetection of Hodgkin's and non-Hodgkin's lymphomas. Successful radioimmunotherapy also has been reported. The purpos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1bb09b3446414584c860f47319ec0659
https://doi.org/10.1002/1097-0142(19940201)73:3+<896::aid-cncr2820731322>3.0.co
https://doi.org/10.1002/1097-0142(19940201)73:3+<896::aid-cncr2820731322>3.0.co
Publikováno v:
Medical Physics. 20:579-582
Trials of radiolabeled antibody therapy in patients with B-cell lymphoma have been the most promising of any in radioimmunotherapy. Response rates of greater than 90% with many complete remissions have been reported by several groups using either low
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82df71296b20f4205d24c6dfe3318377
https://doi.org/10.1118/1.597052
https://doi.org/10.1118/1.597052
Autor:
D M, Goldenberg, R M, Sharkey
Publikováno v:
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of.... 50(4)
Two radiolabeled antibody products for the treatment of non-Hodgkin's lymphoma have been approved, thus indicating that cancer radioimmunotherapy (RAIT) has finally come of age as a new therapeutic modality, exemplifying the collaboration of multiple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::28f92fd1a9958ee01fcba86e66629006
https://pubmed.ncbi.nlm.nih.gov/17043623
https://pubmed.ncbi.nlm.nih.gov/17043623